BioSpace News Archive

Business

Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results

Rigel today announced that it will report its third quarter financial results after market close on Tuesday, November 7, 2017.

October 31, 2017
·
1 min read
Business

InfuSystem to Issue Third Quarter 2017 Financial Results on Friday, November 10, 2017, Before the Market Opens

The Company will also conduct a conference call for all interested investors on Friday, November 10, 2017, at 11:00 a.m.

October 31, 2017
·
1 min read
Business

Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

The collaboration will bring together Arcturus’s LUNAR lipid-mediated delivery platform with Synthetic Genomics’ RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.

October 31, 2017
·
6 min read
Drug Development

Citius Receives Fast Track Designation By FDA For Mino-Lok Investigational Trial

Citius’ investigational program for Mino-Lok is designated “Fast Track” and is currently starting up sites for a phase III trial of Mino-Lok in the U.S.

October 31, 2017
·
4 min read
Pharm Country

Soligenix Announces Pricing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market

Soligenix announced that it has entered into definitive agreements with investors for the purchase and sale of 1,575,500 shares of common stock at a price of $2.00 per share in a registered direct offering and 982,000 shares of common stock at a purchase price of $2.00 per share in a concurrent private placement.

October 31, 2017
·
5 min read
Business

Medizone Appoints Philip Theodore to Executive Team

Medizone today announced the appointment of Philip A. Theodore, as its Executive VP-Operations and Administration, General Counsel and Corporate Secretary.

October 31, 2017
·
3 min read
Drug Development

Enteris BioPharma’s Feasibility-to-Licensing Partner, Cara Therapeutics, Doses First Patient in Phase I Study of Peptelligence-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients

The oral tablet formulation of CR845 was developed in accordance with a Manufacturing and Clinical Supply Agreement between Cara Therapeutics and Enteris whereby Enteris utilized its Peptelligence technology to enable the active ingredient.

October 31, 2017
·
4 min read
Drug Development

Sanofi: Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase III Study of People With Severe Steroid-Dependent Asthma

Dupilumab added to standard therapies significantly reduced the use of maintenance oral corticosteroids (OCS) by 70% on average.

October 31, 2017
·
18 min read